(Q36570839)

15 August 2017

1 reference

title

Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension (English)

1 reference

15 August 2017

C F Opitz

1

1 reference

15 August 2017

R Ewert

series ordinal

2

1 reference

15 August 2017

publication date

1 September 2006

1 reference

European Journal of Clinical Investigation

15 August 2017

published in

1 reference

15 August 2017

volume

36 Suppl 3

1 reference

15 August 2017

page(s)

1-9

1 reference

Endothelin receptor antagonists in pulmonary arterial hypertension.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

The endothelin system in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Synergistic inhibition by BQ-123 and BQ-788 of endothelin-1-induced contractions of the rabbit pulmonary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Necessity of dual blockade of endothelin ETA and ETB receptor subtypes for antagonism of endothelin-1-induced contraction in human bronchi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

EndothelinB receptor-mediated contraction in human pulmonary resistance arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Heterogeneity of endothelin‐sarafotoxin receptors mediating contraction of pig coronary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Emerging role of relaxin in renal and cardiovascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Pulmonary endothelinergic system in experimental congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Hemodynamic effects of bosentan in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Role of endothelin in fibrosis and anti-fibrotic potential of bosentan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Signaling molecules in nonfamilial pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Drug treatment of pulmonary arterial hypertension: current and future agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Endothelin receptor antagonism in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

Pulmonary Fibrosis and Chronic Lung Inflammation in ET-1 Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2006.01691.X

10.1111/J.1365-2362.2006.01691.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference